rc48-adc
RECTAL NEOPLASMS
Fudan Universityantibody_drug_conjugatePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
1 Active assets in the RECTAL NEOPLASMS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pyrotinib Fudan University | Phase 3 | BB |
Same molecule, other indications
rc48-adc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →